Testing DR30206 for advanced or metastatic solid tumors
Part of Cancer clinical trials.
This trial tests a new drug called DR30206 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and how the body processes it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 75 years old.
- You must have an advanced solid tumor that standard treatments no longer work for, or you can't tolerate them.
- You must be in generally good health (able to do most daily activities).
- You must not have certain medical conditions like active infections, heart problems, or autoimmune diseases.
- You must agree to use effective birth control during the study and for 6 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests DFP-14927, a new study drug, in adults with advanced solid tumors that have not responded to standard treatments. It’s designed to see if the drug is safe and to learn how it works in people with limited treatment options.
This trial tests a new drug called PLB-002 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective, especially for cancers that show a specific marker called CLDN6.
This trial tests a new drug called HDM2006 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and effective.
This trial tests a new drug, DR-0202, for people with certain advanced cancers that have not responded to at least two prior treatments. It may be an option if standard treatments are no longer working.
This trial tests a new drug called DR30206 combined with standard therapy for advanced gastrointestinal cancers. It may be an option if you have colorectal, esophageal, gastric, or gastroesophageal junction cancer and have had little or no prior chemotherapy.
This trial tests an experimental drug called DCR-PDL1 for people with advanced solid tumors or non-Hodgkin's lymphoma that has not responded to, progressed on, or could not tolerate standard treatments, or for which no standard treatment exists. The goal is to see if it is safe and how the body processes it.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.